Rigel Pharmaceuticals Acquires U.S. Rights to Gavreto

Rigel Pharmaceuticals announced that it has entered into a definitive agreement to acquire the U.S. rights to pralsetinib (Gavreto) from Blueprint Medicines Corp. Pralsetinib is a once-daily, small-molecule, oral kinase inhibitor of wild-type rearranged during transfection (RET) and oncogenic RET fusions. Pralsetinib is approved by the FDA for the treatment of adult patients with metastatic RET fusion–positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.